CN107860924B - 新型γδT细胞在制备评估AML疗效试剂盒中的应用 - Google Patents
新型γδT细胞在制备评估AML疗效试剂盒中的应用 Download PDFInfo
- Publication number
- CN107860924B CN107860924B CN201710970962.3A CN201710970962A CN107860924B CN 107860924 B CN107860924 B CN 107860924B CN 201710970962 A CN201710970962 A CN 201710970962A CN 107860924 B CN107860924 B CN 107860924B
- Authority
- CN
- China
- Prior art keywords
- cells
- aml
- gamma delta
- curative effect
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000694 effects Effects 0.000 title claims abstract description 26
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 9
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title abstract description 63
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 65
- 238000004393 prognosis Methods 0.000 claims abstract description 16
- 238000011156 evaluation Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 13
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 238000004043 dyeing Methods 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 claims description 3
- 239000012117 Alexa Fluor 700 Substances 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 abstract description 12
- 239000011886 peripheral blood Substances 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000011337 individualized treatment Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 33
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 29
- 239000000872 buffer Substances 0.000 description 21
- 238000011534 incubation Methods 0.000 description 15
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000002969 morbid Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- AEJOEPSMZCEYJN-HXUWFJFHSA-N 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide Chemical compound C([C@@H](N(C)C(=O)CC=1C=C(Cl)C(Cl)=CC=1)C=1C=CC=CC=1)N1CCCC1 AEJOEPSMZCEYJN-HXUWFJFHSA-N 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000037850 immune anergy Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710970962.3A CN107860924B (zh) | 2017-10-18 | 2017-10-18 | 新型γδT细胞在制备评估AML疗效试剂盒中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710970962.3A CN107860924B (zh) | 2017-10-18 | 2017-10-18 | 新型γδT细胞在制备评估AML疗效试剂盒中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107860924A CN107860924A (zh) | 2018-03-30 |
CN107860924B true CN107860924B (zh) | 2019-08-02 |
Family
ID=61696290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710970962.3A Active CN107860924B (zh) | 2017-10-18 | 2017-10-18 | 新型γδT细胞在制备评估AML疗效试剂盒中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107860924B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111504886A (zh) * | 2020-05-06 | 2020-08-07 | 西安交通大学 | 一组分子在制备新冠肺炎辅助诊断试剂或试剂盒中的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109254148A (zh) * | 2018-10-12 | 2019-01-22 | 东莞暨南大学研究院 | 人体外周血t细胞免疫功能精简评估试剂盒及评估方法 |
CN109270265A (zh) * | 2018-10-12 | 2019-01-25 | 东莞暨南大学研究院 | 人体外周血杀伤性免疫细胞功能评估试剂盒及评估方法 |
CN109781987B (zh) * | 2019-01-09 | 2022-04-26 | 暨南大学 | 终末效应t细胞亚群在制备辅助评估再生障碍性贫血病情程度试剂盒中的应用 |
CN109752548B (zh) * | 2019-02-01 | 2022-05-06 | 广州金域医学检验中心有限公司 | 评估慢性淋巴细胞白血病预后的组合试剂及系统 |
CN111621568A (zh) * | 2020-06-23 | 2020-09-04 | 暨南大学 | Brd4-pd-1和/或brd4-pd-l1在制备预测aml预后试剂盒中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106367483A (zh) * | 2016-08-29 | 2017-02-01 | 暨南大学 | TCRγδT细胞亚家族在制备用于预测AML疗效及预后评估试剂盒中的应用 |
-
2017
- 2017-10-18 CN CN201710970962.3A patent/CN107860924B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106367483A (zh) * | 2016-08-29 | 2017-02-01 | 暨南大学 | TCRγδT细胞亚家族在制备用于预测AML疗效及预后评估试剂盒中的应用 |
Non-Patent Citations (3)
Title |
---|
Expression of novel regulatory cell subsets of PD-1high Foxp3+ γδ T cells in de novo AML;Zhenyi Jin等;《Experimetal Hematology》;20170822;第53卷;全文 |
Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia;Zhenyi Jin等;《Journal of Hematology & Oncology》;20161118;第9卷;摘要 |
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse;Valerio Nardone等;《Cancer Biology & Therapy》;20161231;第17卷(第11期);第1213-1220页 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111504886A (zh) * | 2020-05-06 | 2020-08-07 | 西安交通大学 | 一组分子在制备新冠肺炎辅助诊断试剂或试剂盒中的应用 |
CN111504886B (zh) * | 2020-05-06 | 2021-09-03 | 西安交通大学 | 一组分子在制备新冠肺炎辅助诊断试剂或试剂盒中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN107860924A (zh) | 2018-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107860924B (zh) | 新型γδT细胞在制备评估AML疗效试剂盒中的应用 | |
Bryceson et al. | Functional analysis of human NK cells by flow cytometry | |
CN105122067B (zh) | 用于判定急性移植物抗宿主病风险的方法 | |
JPH06505332A (ja) | 総白血球表面抗原を用いた治療法及び診断法 | |
Choi et al. | Diagnostic value of peripheral blood immune profiling in colorectal cancer | |
JP7535046B2 (ja) | 毛球部毛根鞘細胞を同定する方法 | |
KR102268963B1 (ko) | 머신러닝 기법으로 말초혈액 내 암 면역력을 평가하여 암을 진단하거나 치료반응을 예측하는 방법 및 이를 이용한 진단키트 | |
CN106255886B (zh) | 检测活运动神经元蛋白质的表达的方法 | |
JP2021531816A (ja) | 骨髄系由来サプレッサー細胞亜集団の検出および単離 | |
CN109781987A (zh) | 终末效应t细胞亚群在制备辅助评估再生障碍性贫血病情程度试剂盒中的应用 | |
US20210270812A1 (en) | Method for analyzing immune cells | |
Mihalcioiu et al. | Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology | |
CN109477838A (zh) | 利用受体协同活性的nk细胞的活性检查方法及利用其的与nk细胞的活性关联的疾病的诊断方法 | |
AU764745B2 (en) | Use of an antibody to detect basophiles and/or mast cells | |
Tomita et al. | CD45RA-CD25highCD127-CD4+ activated regulatory T cells are correlated with de novo donor-specific anti-HLA antibody formation after kidney transplantation in standard immunosuppression | |
CN113238058B (zh) | 一种测评car-t治疗起始t细胞的方法 | |
Camisaschi et al. | Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients | |
Popa et al. | Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest | |
Pojero et al. | MGUS and multiple myeloma: looking for “new” markers and exploring the interaction with the bone marrow microenvironment. | |
CN114371282A (zh) | 一种评估抗原沉默效应对抗体药效影响的方法及其应用 | |
CN118443940A (zh) | Sp70在制备肺癌pd-1/pd-l1阻断治疗疗效预测试剂中的应用 | |
CN116679059A (zh) | 单个细胞表面抗原表达数量定量方法 | |
Drakos et al. | Clinical cytometry in the cloud: an ESCCA project to bring cytometry data to modern multidisciplinary translational research platforms | |
Popov et al. | Minimal Residual disease monitoring by simplified flow cytometry assay in children with pre-b-cell acute lymphoblastic leukemia: advantages and limitations | |
JP2018163019A (ja) | がんの再発の予測を補助する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221115 Address after: 201800 Zone B, Floor 4, Building 2, No. 4997 Bao'an Road, Jiading District, Shanghai Patentee after: Shanghai Purui Medical Laboratory Co.,Ltd. Address before: 510632 No. 601, Whampoa Avenue, Tianhe District, Guangdong, Guangzhou Patentee before: Jinan University |
|
CP03 | Change of name, title or address |
Address after: 201800 Zone B, Floor 4, Building 2, No. 4997 Bao'an Road, Jiading District, Shanghai Patentee after: Shanghai Puyouji Medical Laboratory Co.,Ltd. Country or region after: China Address before: 201800 Zone B, Floor 4, Building 2, No. 4997 Bao'an Road, Jiading District, Shanghai Patentee before: Shanghai Purui Medical Laboratory Co.,Ltd. Country or region before: China |